Skip to content

The efficacy of "transcutaneous low level vagus nerve stimulation" for preventing postoperative atrial fibrillation after cardiac valvular surgery under cardiopulmonary bypass: A randomized controlled, double-blind, interventional study.

The efficacy of "transcutaneous low level vagus nerve stimulation" for preventing postoperative atrial fibrillation after cardiac valvular surgery under cardiopulmonary bypass: A randomized controlled, double-blind, interventional study.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400080750
Enrollment
Unknown
Registered
2024-02-06
Start date
2024-09-05
Completion date
Unknown
Last updated
2026-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Atrial Fibrillation in Valve Surgery under Cardiopulmonary Bypass

Interventions

Sham stimulation group:Patients receive treatment of the same duration. For sham stimulation, electrodes are placed on the right cymba conchae without electrical stimulation applied.

Sponsors

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Age >=18 years; 2. Diagnosed as valvular heart disease and scheduled for elective mitral and/or aortic valve surgery under general anesthesia with cardiopulmonary bypass; 3. American Society of Anesthesiologists (ASA) classification 1-3; 4. Patients are capable of understanding the study procedures and using various assessment tools, and be able to communicate effectively with the research team; 5. Voluntarily participating in this study and signing the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with permanent atrial fibrillation or implantation of left or right ventricular assist devices; 2. Patients who do not require cardiopulmonary bypass; 3. Patients requiring deep hypothermic circulatory arrest; 4. Patients with active infection or sepsis; 5. Preoperative use of immunosuppressive drugs (including steroids); 6. Patients with immunodeficiency syndrome; 7. Patients with known neurological disorders; 8. Patients currently participating in other clinical trials; 9. Patients with auricular dermatitis; 10. History of seizures or syncope within the last 5 years; 11. Patients who have undergone vagus nerve stimulation or acupuncture treatment in the month preceding the study; 12. Vulnerable populations, including those with mental illness, cognitive impairment, critically ill patients, minors, pregnant women, etc.

Design outcomes

Primary

MeasureTime frame
postoperative AF incidence;AF duration was measured based on Holter monitoring recordings for 7 days postoperatively.;

Secondary

MeasureTime frame
patients demographic information and baseline: height, weight, gender, age, history of hypertension, history of diabetes, and preoperative hemoglobin concentration. ;Operation duration, cardiopulmonary bypass duration, crystalloid infusion volume, blood transfusion volume, urine output, postoperative hemoglobin concentration and respiratory supporting duration in ICU (hours) ;Vital signs including blood pressure and heart rate in four time-frames.;CRP;Creatinine;IL-6;IL-10;TNF-a;prognosis;

Countries

China

Contacts

Public ContactGang Chen

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

chengang120@hotmail.com+86 137 5711 8681

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Sep 19, 2026